All blood samples were taken in fasting condition at 9 a.m. at least 2 h after the last dose of ASA. Standard laboratory techniques were used for regular laboratory testing. Serum BDNF concentrations were measured using BDNF Quantikine Immunoassay (R&D Systems, USA) as previously described for our laboratory [14 (link)]. ELISA kits were also used to determine concentrations of the following parameters: serum TXB2 (EIA kits, Cayman Chemicals, Ann Arbor, MI, USA), von Willebrand factor (vWF) molecule (vWF: Ag), tumor necrosis factor (TNF)-α (Quantikine® HS ELISA Human TNF-α Immunoassay), interleukin (IL)-6 (Quantikine® HS ELISA Human IL-6 Immunoassay; both R&D Systems, Inc., Minneapolis, USA), soluble CD40 ligand (sCD40L; Human soluble CD40 Ligand Immunoassay, R&D Systems, Inc., NE, USA), and soluble P-selectin (human P-selectin/CD62P ELISA kit R&D Systems, Inc., Minneapolis, USA). High-sensitivity C-reactive protein (hsCRP) concentrations were assessed using a Cobas Integra 800 device (Roche, Basel, Switzerland), as previously described [21 (link),22 (link)]. The compliance with ASA treatment was defined according to previously described criteria [20 (link)].